Clinical trials: Metastatic Nonsmall Cell Lung Cancer
Non Small Cell Lung Cancer
Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer
The purpose of this phase 1b/2 study is to estimate the treatment effect of study drug measuring progression free survival.
- Trial name
- NCT01666977
- Testing
- AMG 386, Pemetrexed, Carboplatin
- Where
- 35 sites in United States, Australia and 4 more
- Volunteers
- 36 people
- Sponsor
- Amgen
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene.
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03831932
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
Solid Tumor
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as…
- Trial name
- NCT03085914
- Testing
- Epacadostat, Pembrolizumab, Oxaliplatin
- Where
- 16 sites in United States
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Lung Cancer
PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer
Immunotherapy is probably, since the development of therapies targeting EGFR mutations or ALK rearrangement, the most attractive therapeutic perspective in the management of metastatic lung cancer.
- Trial name
- IMMUNO-PREDICT (NCT02827344)
- Testing
- blood sample collection for CTC and MDSC analysis
- Where
- France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Toulouse
Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Abscopal Effect for Metastatic Non-small Cell Lung Cancer.
Patients with Non-small cell lung cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1.
- Conditions
- Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Radiotherapy, Thymalfasin
- Trial name
- NCT02542930
- Testing
- Radiotherapy, Thymalfasin
- Sponsor
- Zhejiang Provincial People's Hospital
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Metastatic Nonsmall Cell Lung Cancer
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
The goal of this non-interventional study is to emulate the KEYNOTE-189 randomized controlled trial of pembrolizumab for the treatment of metastatic non-small cell lung cancer using real-world, electronic health record data.
- Trial name
- NCT06607393
- Testing
- Pembrolizumab, Pemetrexed, Cisplatin
- Volunteers
- 851 people
- Sponsor
- Aetion, Inc.
Carcinoma, Non-Small-Cell Lung
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
- Trial name
- NCT06140836
- Testing
- Repotrectinib, Crizotinib
- Where
- 122 sites in United States, Argentina and 19 more
- Volunteers
- 190 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether polyglutamate paclitaxel is more effective than docetaxel in treating non-small…
- Trial name
- NCT00054184
- Testing
- docetaxel, paclitaxel poliglumex
- Where
- 35 sites in United States
- Volunteers
- 350 people
- Sponsor
- CTI BioPharma
Brain Metastases, Lung Cancer Metastatic
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
The study will use an Ommaya reservoir that drains into brain metastases to deliver activated, autolous dendritic cells to the tumor lesion, for patients who are 18 - 75 years old who have brain metastases from either lung cancer…
- Conditions
- Brain Metastases, Lung Cancer Metastatic, Breast Cancer Metastatic
- Trial name
- NCT03638765
- Testing
- DCVax-Direct
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwest Biotherapeutics
Non-small Cell Lung Cancer (NSCLC)
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targets specific proteins on cancer cells.
- Trial name
- NCT07566052
- Testing
- Setidegrasib, Docetaxel
- Where
- 23 sites in United States, China and 1 more
- Volunteers
- 356 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
- Trial name
- NCT04984811
- Testing
- efineptakin alfa, Atezolizumab
- Where
- 22 sites in United States
- Volunteers
- 33 people
- Sponsor
- NeoImmuneTech
Non Small Cell Lung Cancer
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
This study aims to investigate the efficacy and safety of fecal microbiota transplantation (FMT) as a treatment for non-small cell lung cancer (NSCLC) patients whose disease has progressed after immune checkpoint inhibitor (ICI)…
- Trial name
- FMT-LUNG (NCT07432984)
- Testing
- Tislelizumab, Fecal Microbiota Transplant(FMT)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Se-Hoon Lee
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of YL202 in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT07202364
- Testing
- YL202
- Where
- China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
- Trial name
- NCT02954991
- Testing
- Glesatinib, Sitravatinib, Mocetinostat
- Where
- 25 sites in United States
- Volunteers
- 161 people
- Sponsor
- Mirati Therapeutics Inc.
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer
The purposes of this study are to test whether the addition of cisplatin to single agent chemotherapy (either gemcitabine or pemetrexed) prolongs survival in elderly patients with non squamous non small cell lung cancer (NSCLC)…
- Trial name
- MILES-4 (NCT01656551)
- Testing
- Gemcitabine, Pemetrexed, Cisplatin
- Where
- 48 sites in Italy
- Volunteers
- 232 people
- Sponsor
- National Cancer Institute, Naples
Colorectal Cancer, Non-Small Cell Lung Cancer
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.
- Trial name
- NCT05954871
- Testing
- GDC-1971, Osimertinib, Cetuximab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Genentech, Inc.
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Phase II trial to study the effectiveness of combining suramin, paclitaxel, and carboplatin in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00006929
- Testing
- suramin, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab as firstline treatment for patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT06448312
- Testing
- SKB264, Pembrolizumab
- Where
- 64 sites in China
- Volunteers
- 406 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.